Global Mental Health Summit

The American Ibogaine initiative represents a bipartisan ibogain research bill breakthrough in U.S. mental health policy, connecting New York State and Texas, and US based opioid abatement legislation and advocacy through a unified clinical research consortium and with Private Public Sector Partnership for Access and Benefit-Sharing (ABS) framework for sustainable ibogaine production in West Africa, Gabon, Ghana, Cameroon, DRC, and in the Amreicas such as Costa Rica, Brazil, and others tropical nations for forever forest biodiversity program..

The KRFI’s Questors Contract Research Organization (CRO) and Clinical Trial Management System (CTMS) platform, support the FDA Investigational New Drug (IND) application for ibogaine and Psychedelics to accelerate cross-border data integration for clinical, regulatory compliance, tracibility for the mental health products.. ​The Knowledge Recovery Foundation/ Institute (KRFI), is a  Public Benefit Corporation, a 501(c)(3) not for profit research and clinical development organization. 

 

The American Ibogaine Initiative: A Bipartisan support to NYS Ibogaine Research Bill requires your support for Governor Hochul's sign off during the January General Senate Assembly in NYS, Albany.  We request your Ibogaine testimonials for the Assembly bill.  KRFI Questors Online Hybrid Global Mental Health Summit for Global Drug Policy Coalition for Global Mental Health Summit.   

 

In May, 2026,  KRFI Questors Gala Award Dinner Benefit Event for the Ibogaine Clinical Trial is now planned at the New York Academy of Medicine.

 

On December 11–12th, 2025, The December 12th event will address the American Ibogaine initiatives introduces the Global Mental Health Security Fund’s by the Private Public Sector Partnership for matching fund development for the opioid FDA Clinical Trial Grant funding.

The fund aims to support the OASAS Commission and Governor Hochul for signing of the NYS Bipartisan Ibogaine Research Bill, a grant to support the nation’s first-ever consortium for FDA clinical trial for ibogaine treatment for Opioid Use Disorder (OUD) / Substance Use Disorder, TBI, and other conditions like Parkinson's Diseases.    

This historic Ibogaine research bill initiative unites state leadership, federal regulators, scientific researchers, and global public–private partners to advance safe, ethical, and science-based clinical access to ibogaine, a plant-derived compound showing potential to transform addiction treatment and mental health care.